Ixekizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ixekizumab: From Psoriasis to Rheumatoid Vasculitis
One-Sentence Summary
Ixekizumab is an anti-IL-17A monoclonal antibody originally used for psoriasis and related Th17-driven inflammatory diseases. The TxGNN model predicts it may be relevant to Rheumatoid Vasculitis, but this direction is currently supported only by 1 low-relevance clinical trial and 0 publications, and the underlying mechanistic rationale is contested.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Psoriasis / psoriatic arthritis / ankylosing spondylitis (based on known drug class; no Danish marketing-authorisation record available) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 97.53% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available on file for this candidate (marked as a data gap). Based on known drug class information, Ixekizumab is an anti-IL-17A monoclonal antibody, originally developed for Th17-driven inflammatory diseases — psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Rheumatoid vasculitis, by contrast, is primarily driven by immune-complex deposition and inflammatory vessel-wall injury, a mechanism that does not have an established link to the IL-17A pathway. The evidence pack’s own mechanistic assessment flags this directly: IL-17 inhibitors are more frequently reported in the literature as inducers of paradoxical vasculitis reactions than as treatments for vasculitis. This means the predicted direction may run counter to the drug’s actual clinical safety profile, rather than representing a genuine therapeutic opportunity.
The single supporting clinical trial identified (NCT07138898) was also independently graded C (low relevance) — it studies perioperative immunosuppressant management in rheumatology patients undergoing shoulder arthroplasty, and does not evaluate Ixekizumab’s efficacy in rheumatoid vasculitis specifically. Taken together, this prediction should be treated as a statistical association from the knowledge graph rather than a biologically well-supported hypothesis.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Evaluates perioperative immunosuppressant withdrawal strategies in rheumatology patients undergoing elective total shoulder arthroplasty; not focused on Ixekizumab efficacy in rheumatoid vasculitis (relevance graded C — low). |
Literature Evidence
Currently no related literature available.
Denmark Market Information
Ixekizumab currently has no marketing authorisation on record in Denmark (market status: Not marketed; 0 authorisations).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L5 (model prediction only) — supported by just one low-relevance (grade C) clinical trial and no literature. The proposed mechanistic link is not only unproven but potentially contradicted by post-marketing reports of IL-17 inhibitors inducing, rather than treating, vasculitis.
To proceed, the following is needed:
- Confirmed mechanism-of-action documentation for Ixekizumab (currently a data gap)
- Danish/EU SmPC warnings and contraindications, including any noted vasculitis-related adverse events (currently a blocking data gap)
- Targeted literature or pharmacovigilance review specifically addressing IL-17A inhibition and vasculitis risk vs. benefit
- A clinical trial or case series directly evaluating Ixekizumab in rheumatoid vasculitis before any further evidence-stage progression
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.